（股份代 號：399） 延長最後截止日期 茲提述本公司日期為二零二五年七月十五日及二零二五年七月十六日的公告（「該 等公告」），內容有關張彪兵及陳靜按每股認購股份0.3124港元的認購價分別認 購本公司60,000,000股股份及30,000,000股股份。除文義另有規定外，本公告所 用詞彙與該等公告所界定者具有相同涵義。 認購協議A INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立並於百慕達存續之有限公 司） 領航醫藥及生物科技有限公司 由於需要額外時間達成認購協議A所載的先決條件，故本公司已於二零二五年 八月五日與認購人A訂立延長函件，以將最後截止日期由二零二五年八月五日 延長至二零二五年八月二十六日或認購人A與本公司可能書面協定的其他日期 及時間。 除上文所述者外，補充協議A（經補充協議A修訂及補充）的所有其他條 ...

领航医药生物科技港交所公告，董事会建议将公司英文名称由"Innovative Pharmaceutical Biotech Limited"更改为"Starcoin Group Limited"，并采纳中文名称"星太链集团有限公司"为公司之第二名称，以 取代现有名称"领航医药及生物科技有限公司"。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 領航醫藥及生物科技有限公司 呈交日期： 2025年7月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 00399 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 股東週年大會通告 茲通告領航醫藥及生物科技有限公司（「本公司」）謹訂於二零二五年八月二十九日 （星期五）上午十一時正於香港灣仔港灣道4號灣景國際二樓宴會廳1-2舉行股東週年大會， 藉以： 作為普通事項 – 1 – 1. 省覽及採納截至二零二五年三月三十一日止年度之經審核財務報表及本公 司董事（「董事」）與核數師（「核數師」）之報告。 2. (i) 重選仰融博士為執行董事； (ii) 重選高源興先生為執行董事； (iii) 重選唐榕先生為執行董事； (iv) 重選齊淑娟女士為執行董事； (v) 重選龍凡博士為執行董事； (vi) 重選伍鳴博士為執行董事； (vii) 重選張慎先生為執行董事； (viii) 重選張羿先生為 ...

INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) （於開曼群島註冊成立並於百慕達存續之有限公 司） （Stock Code股份代 號：399） NOTIFICATION LETTER 通知信函 Dear Non-registered Shareholder(s) (Note 1), 31 July 2025 Innovative Pharmaceutical Biotech Limited (the "Company") – Notice of Publication of (a) Annual Report 2025, (b) Circular dated 31 July 2025 in relation to (1) Proposed Change of Company Name; (2) Proposed increase in Authorised Share Capit ...

INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) （於開曼群島註冊成立並於百慕達存續之有限公 司） （Stock Code股份代 號：399） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders. 31 July 2025 Innovative Pharmaceutical Biotech Limited (the "Company") – Notice of Publication of (a) Annual Report 2025, (b) Circular dated 31 July 2025 in relation to (1) Proposed Change of Company Name; (2) Proposed increase in Authorised Share Capital; (3) Propose ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證 券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有領航醫藥及生物科技有限公司之股份，應立即將本通函連同隨附 之代表委任表格送交買主或承讓人，或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便 轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不會就因本通函全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） (1) 建議更改公司名稱； (2) 建議增加法定股本； (3) 建議授予發行股份及回購股份之一般授權； (4) 重選董事； 及 (5) 股東週年大會通告 董事會函件載於本通函第3至第9頁。本公司謹訂於二零二五年八月二十九日（星期五）上午十一 時正於香港灣仔港灣道4號灣景國際二樓 ...

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability) ( 於開曼群島註冊成立並於百慕達存續之有限公司) (Stock Code 股份代號：399) ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024/25 環境、社會及管治報告 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) ( 於開曼群島註冊成立並於百慕達存續之有限公司) (Stock Code 股份代號：399) Annual Report 2025 年 報 序言 關於本集團 領航醫藥及生物科技有限公司（「本公司」，連同其 附屬公司統稱「本集團」或「我們」）是一家從事醫藥 及生物科技業務的香港投資控股公司，經營業務 主要由兩個部分組成，包括(a)香港的美容產品貿 易（「美 容 產 品 貿 易」）；(b)口服胰島素產品的研發 及商品化（「研發」）。 本 環 境、社 會 及 管 治 ...

[Corporate Information](index=2&type=section&id=Corporate%20Information) [Overview of Corporate Information](index=2&type=section&id=Corporate%20Information) This chapter provides fundamental company information, including board members, committee structures, registered office, principal place of business, share registrar, auditor, and principal bankers, noting significant changes in board composition during and after the reporting period - The company's board of directors underwent significant restructuring during and after the FY2025 reporting period, with changes in executive, non-executive, and independent non-executive directors, including the appointment of Mr. Yang Rong as the new Chairman on March 25, 2025[5](index=5&type=chunk)[6](index=6&type=chunk) - The company's auditor is SFAI (HK) CPA Limited, and its principal banker is Bank of Communications Co, Ltd[10](index=10&type=chunk) [Chairman's Statement](index=4&type=section&id=Chairman%27s%20Statement) [Chairman's Statement](index=4&type=section&id=Chairman%27s%20Statement) The Chairman's Statement highlights the Group's commitment to strategic priorities amidst challenging operating conditions, noting delays in oral insulin commercialization due to clinical trial setbacks and active exploration of strategic investments in emerging technologies like blockchain and Web 3.0 for business diversification - The commercialization timeline for the core product, oral insulin (in Phase III clinical trials), has been further delayed to **Q3 2028**, primarily due to unexpected challenges in expanding sample size and introducing new hospitals[13](index=13&type=chunk)[17](index=17&type=chunk) - The Group is actively exploring strategic investments in emerging technologies, particularly focusing on blockchain and Web 3.0, recognizing their disruptive potential across supply chain, healthcare, finance, and data security[14](index=14&type=chunk)[19](index=19&type=chunk) - The Group is optimistic about the significant potential of the diabetes market in mainland China and plans to secure sufficient funding for the final development and commercialization phases of the oral insulin product through collaborations with research institutions, expanding clinical trial partners, and seeking strategic financing[15](index=15&type=chunk)[16](index=16&type=chunk)[18](index=18&type=chunk) [Management Discussion and Analysis](index=6&type=section&id=Management%20Discussion%20and%20Analysis) [Business Review](index=7&type=section&id=Business%20Review) This fiscal year, the Group turned from profit to loss, primarily due to a significant impairment loss on intangible assets related to the oral insulin project, a substantial decline in beauty equipment trading revenue, and the postponement of the oral insulin commercialization timeline to Q3 2028 due to clinical trial setbacks, alongside the issuance and amendment of convertible bonds with a major shareholder [Group Results](index=7&type=section&id=Group%20Results) This fiscal year, the Group's revenue significantly decreased by **68.3%** year-on-year, primarily due to reduced beauty equipment and product trading, resulting in a shift from profit to loss mainly driven by an approximately **HKD 297 million** impairment loss on intangible assets | Metric | FY2025 (HKD) | FY2024 (HKD) | YoY Change | | :--- | :--- | :--- | :--- | | **Revenue** | Approx. 2,091,000 | Approx. 6,593,000 | -68.3% | | **(Loss) / Profit attributable to owners of the Company** | Approx. (345,937,000) | Approx. 103,403,000 | Turned from profit to loss | - The primary reason for the shift from profit to loss was an approximately **HKD 297 million** impairment loss on intangible assets recorded this fiscal year[27](index=27&type=chunk)[32](index=32&type=chunk) [Research and Development Progress](index=7&type=section&id=Research%20and%20development) The commercialization timeline for the core oral insulin R&D project has been postponed from Q1 2026 to Q3 2028 due to challenges in clinical trial recruitment and sample size expansion, leading to an approximately **HKD 297 million** impairment loss on intangible assets due to this delay and a shift from in-house manufacturing to outsourcing, while the company secured capital support from a major shareholder and renewed its cooperation agreement with Tsinghua University until June 2027 - The commercialization timeline for oral insulin products has been delayed from **Q1 2026** to **Q3 2028** due to clinical trial progress challenges[36](index=36&type=chunk)[37](index=37&type=chunk)[39](index=39&type=chunk) - Due to commercialization delays and changes in production plans (shifting to subcontracted manufacturing to save startup costs), the company assessed the **HKD 1.37 billion** intangible assets under development, recognizing an impairment loss of approximately **HKD 297 million**[46](index=46&type=chunk)[49](index=49&type=chunk) - To ensure project advancement, the Group committed to investing no less than **HKD 12 million** annually in product R&D starting April 2025, securing a major shareholder's capital support pledge to compensate for asset value loss if the product is not successfully commercialized by **Q3 2028**[47](index=47&type=chunk)[48](index=48&type=chunk) - The Group's cooperation agreement with Tsinghua University for oral insulin products has been renewed, with the new term extending to **June 30, 2027**[50](index=50&type=chunk)[54](index=54&type=chunk) [Convertible Bonds Issued](index=11&type=section&id=Convertible%20bonds%20issued%20by%20the%20Company) During the reporting period, the company agreed with major shareholder Dr. Mao Yumin to issue new convertible bonds totaling **HKD 55.5 million** to offset an equivalent amount of shareholder loans, while also amending terms for some existing convertible bonds held by Dr. Mao and his associates, including extending maturity dates to twenty years post-issuance and adjusting conversion prices, with these transactions completed on June 21, 2024 - The company issued new convertible bonds with a principal amount of **HKD 55.5 million** to major shareholder Dr. Mao Yumin, used to offset an equivalent amount of shareholder loans[51](index=51&type=chunk)[52](index=52&type=chunk) - The company amended certain terms of the **HKD 360 million** outstanding convertible bonds held by major shareholder Dr. Mao and his associates, extending the maturity date for some bonds to twenty years after issuance and reducing the conversion price for others from **HKD 0.40** to **HKD 0.202**[56](index=56&type=chunk)[60](index=60&type=chunk)[65](index=65&type=chunk) [Prospects](index=14&type=section&id=Prospects) Despite challenges, the company remains optimistic about its prospects, continuing to advance the commercialization of oral insulin products with significant potential in the Chinese market, while also planning to expand into blockchain technology by developing infrastructure and key technologies to explore new business models and revenue streams for diversification - The company will continue to collaborate closely with Contract Research Organizations (CROs) and strengthen its project team to ensure the oral insulin R&D project completes commercialization as planned by **Q3 2028**[68](index=68&type=chunk)[73](index=73&type=chunk) - The company plans to expand its business into the blockchain technology sector, focusing on the research and development of underlying infrastructure and key technologies to enhance transparency, security, and efficiency in digital and commercial transactions, seeking new growth opportunities[70](index=70&type=chunk)[73](index=73&type=chunk) [Financial Review](index=15&type=section&id=Financial%20Review) As of March 31, 2025, the Group's bank and cash balances were approximately **HKD 3.7 million**, with total borrowings around **HKD 1.049 billion**, while the current ratio decreased from **0.03** to **0.01** and the debt-to-equity ratio increased from **0.77** to **0.98**, indicating increased liquidity pressure and higher financial leverage, with no significant investments or asset pledges this fiscal year, and a total of **20** employees with decreased staff costs year-on-year | Metric | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | **Bank and Cash Balances** | Approx. HKD 3.7 million | Approx. HKD 3.1 million | | **Total Borrowings** | Approx. HKD 1.0492 billion | Approx. HKD 1.0542 billion | | **Current Ratio** | 0.01 | 0.03 | | **Debt-to-Equity Ratio** | 0.98 | 0.77 | - As of March 31, 2025, the Group had **20** full-time employees, with total staff costs (including directors' emoluments) for the fiscal year approximately **HKD 5.5 million**, a decrease from **HKD 6.1 million** in the previous fiscal year[85](index=85&type=chunk)[86](index=86&type=chunk)[92](index=92&type=chunk) [Management Profile](index=17&type=section&id=Management%20Profile) [Management Profile](index=17&type=section&id=Management%20Profile) This chapter details the backgrounds and professional experiences of the company's executive, non-executive, independent non-executive directors, and senior management, notably highlighting new members like Dr. Long Fan and Dr. Wu Ming, whose deep academic and research backgrounds in computer science, system security, and blockchain align with the company's strategic expansion into blockchain technology - New Executive Director Dr. Long Fan holds a Ph.D. in Computer Science from MIT, with research interests in system security and blockchain, and is the founder and president of Conflux Research Institute[106](index=106&type=chunk)[107](index=107&type=chunk) - New Executive Director Dr. Wu Ming holds a Ph.D. from the Institute of Computing Technology, Chinese Academy of Sciences, is the co-founder and CTO of Conflux Research Institute, and previously served as a Senior Researcher at Microsoft Research Asia[108](index=108&type=chunk)[110](index=110&type=chunk)[112](index=112&type=chunk) - New Executive Director Mr. Zhang Shen and Non-Executive Director Mr. Zhang Yi possess extensive experience in FinTech, blockchain technology integration, and software development, serving as CEO and CTO of Mercury Labs Pty Ltd, respectively[113](index=113&type=chunk)[115](index=115&type=chunk) [External Consultant Profile](index=22&type=section&id=External%20Consultant%20Profile) [External Consultant Profile](index=22&type=section&id=External%20Consultant%20Profile) This chapter outlines the profile of Dr. Mao Yumin, the company's Chief Scientific Advisor and Honorary Chairman, who, as a major shareholder, possesses extensive experience in bio- and genetic engineering, providing consulting services for the Group's gene testing products and other scientific technology R&D - Major shareholder Dr. Mao Yumin serves as Chief Scientific Advisor and Honorary Chairman, providing consulting services for the Group's gene testing products and other scientific research projects[134](index=134&type=chunk)[135](index=135&type=chunk) [Corporate Governance Report](index=23&type=section&id=Corporate%20Governance%20Report) [Corporate Governance Practices](index=24&type=section&id=Corporate%20Governance%20Practices) This report outlines the company's corporate governance structure and practices, noting compliance with most code provisions during the period, except for the non-separation of Chairman and CEO roles, and highlights the auditor's disclaimer of opinion on the company's going concern ability due to significant losses and net current liabilities, detailing management's mitigating plans [Board of Directors and Committees](index=24&type=section&id=Board%20of%20Directors%20and%20Committees) This section describes the composition, responsibilities, and annual activities of the Board of Directors and its Remuneration, Nomination, and Audit Committees, noting the Board's oversight of financial performance and strategy, and the committees' roles in remuneration policies, director nominations, financial reporting review, and internal controls, while highlighting non-compliance with the code provision requiring separate roles for Chairman and CEO, with the CEO position remaining vacant - The company failed to comply with the corporate governance code provision requiring the separation of Chairman and Chief Executive Officer roles, with the CEO position remaining vacant as of the reporting date[152](index=152&type=chunk)[153](index=153&type=chunk) - The Audit Committee held **four** meetings this fiscal year, reviewing annual and interim results, the effectiveness of risk management and internal control systems, and considering the re-appointment of external auditors[182](index=182&type=chunk)[184](index=184&type=chunk) [Auditor's Disclaimer of Opinion](index=33&type=section&id=Disclaimer%20of%20Opinion) The auditor issued a 'Disclaimer of Opinion' on the Group's consolidated financial statements for this fiscal year, primarily due to significant uncertainties regarding the Group's going concern ability, evidenced by substantial losses, large net current liabilities, and net current liabilities, as management's mitigating plans (e.g., debt restructuring, new financing, cost control) are preliminary and lack definitive written agreements, preventing the auditor from obtaining sufficient evidence to assess their success or the appropriateness of the going concern assumption - The auditor explicitly issued a 'Disclaimer of Opinion' as they were unable to form an audit opinion on the consolidated financial statements[190](index=190&type=chunk)[363](index=363&type=chunk) - Key factors leading to the disclaimer include a fiscal year loss of approximately **HKD 346 million**, net current liabilities of approximately **HKD 963 million**, and a deficit attributable to owners of the company of approximately **HKD 681 million** as of March 31, 2025[193](index=193&type=chunk)[364](index=364&type=chunk) - Management has formulated several plans to address liquidity issues, including convertible bond restructuring, new capital and financing initiatives (such as share placements and rights issues), and stringent cost control measures, supported by financial commitments from major shareholders[208](index=208&type=chunk)[211](index=211&type=chunk) [Report of the Directors](index=45&type=section&id=Report%20of%20the%20Directors) [Report of the Directors](index=45&type=section&id=Report%20of%20the%20Directors) This report covers statutory disclosures including the company's principal activities, business review, key risks, financial position, share capital movements, directors' and major shareholders' interests, and connected transactions, noting no dividend proposals or share repurchases during the period, and highlighting significant interests of major shareholder Dr. Mao Yumin and his associates in convertible bond issuance and amendments, as well as his ongoing connected transactions as Chief Scientific Advisor - The Board does not recommend the payment of a final dividend for this fiscal year[270](index=270&type=chunk) | Shareholder Name | Capacity | Number of Shares / Relevant Shares Held | Percentage of Issued Share Capital | | :--- | :--- | :--- | :--- | | Dr. Mao Yumin | Beneficial Owner / Interest of Controlled Corporation | 1,804,955,947 (L) / 102,374,770 (L) | 99.05% / 5.62% | | Zhou Yaoting | Beneficial Owner | 364,355,000 (L) | 19.99% | - During and after the reporting period, the company engaged in multiple connected transactions with major shareholder Dr. Mao Yumin, including the issuance of **HKD 55.5 million** convertible bonds to offset shareholder loans and the amendment of terms for his existing convertible bonds[312](index=312&type=chunk)[314](index=314&type=chunk) - The company has ongoing connected transactions with major shareholder Dr. Mao Yumin, engaging him as Chief Scientific Advisor with a monthly service fee of **HKD 56,000**, and the agreement has been renewed until **2025**[325](index=325&type=chunk) [Independent Auditor's Report](index=58&type=section&id=Independent%20Auditor%27s%20Report) [Independent Auditor's Report](index=58&type=section&id=Independent%20Auditor%27s%20Report) Independent auditor SFAI (HK) CPA Limited issued a 'Disclaimer of Opinion' on the company's consolidated financial statements for the year ended March 31, 2025, primarily due to significant uncertainties related to going concern, including substantial group losses and large net current liabilities, as management's liquidity improvement plans are preliminary and lack sufficient supporting evidence, preventing the auditor from forming an opinion on the appropriateness of the going concern assumption - The auditor explicitly issued a 'Disclaimer of Opinion' as they were unable to form an audit opinion on the consolidated financial statements[363](index=363&type=chunk) - The basis for the disclaimer is a scope limitation related to the 'appropriateness of the going concern accounting basis,' specifically due to the Group incurring a loss of approximately **HKD 346 million** for the year ended March 31, 2025, along with net current liabilities of approximately **HKD 963 million** and a deficit attributable to owners of the company of approximately **HKD 681 million**[364](index=364&type=chunk)[366](index=366&type=chunk) - Although management has formulated multiple plans to improve liquidity, the auditor could not obtain sufficient evidence to assess the likelihood of these plans' success or confirm the appropriateness of the going concern assumption, as their implementation is in preliminary stages and lacks supporting documentation like written agreements[372](index=372&type=chunk) [Consolidated Financial Statements](index=63&type=section&id=Consolidated%20Financial%20Statements) [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=63&type=section&id=Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) This fiscal year, the Group's revenue was **HKD 2.091 million**, a **68.3%** year-on-year decrease, resulting in an annual loss of **HKD 570 million** (compared to a **HKD 98.707 million** profit last fiscal year) due to an **HKD 297 million** intangible asset impairment loss and **HKD 260 million** in finance costs, with a loss attributable to owners of **HKD 346 million** and basic loss per share of **20.01 HK cents** | Item (HKD thousands) | FY2025 | FY2024 | | :--- | :--- | :--- | | **Revenue** | 2,091 | 6,593 | | **Gross Profit** | 188 | 840 | | **Impairment Loss on Intangible Assets** | (296,984) | — | | **Finance Costs** | (260,099) | (218,097) | | **(Loss) / Profit for the Year** | (570,346) | 98,707 | | **(Loss) / Profit attributable to owners of the Company** | (345,937) | 103,403 | | **Basic (Loss) / Earnings Per Share (HK cents)** | (20.01) | 6.77 | [Consolidated Statement of Financial Position](index=65&type=section&id=Consolidated%20Statement%20of%20Financial%20Position) As of March 31, 2025, the Group's total assets were **HKD 1.085 billion**, total liabilities **HKD 1.060 billion**, and net assets significantly reduced to **HKD 25.341 million**, with net current liabilities expanding from **HKD 382 million** to **HKD 963 million**, indicating increased short-term solvency pressure, while intangible assets decreased from **HKD 1.373 billion** to **HKD 1.076 billion** due to impairment, and the deficit attributable to owners of the company expanded from **HKD 612 million** to **HKD 681 million** | Item (HKD thousands) | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | **Non-current Assets (primarily Intangible Assets)** | 1,076,240 | 1,373,224 | | **Current Assets** | 8,889 | 9,799 | | **Current Liabilities** | 972,065 | 391,601 | | **Net Current Liabilities** | (963,176) | (381,802) | | **Non-current Liabilities** | 87,723 | 671,991 | | **Net Assets** | 25,341 | 319,431 | | **Deficit attributable to owners of the Company** | (681,193) | (611,512) | [Consolidated Statement of Cash Flows](index=69&type=section&id=Consolidated%20Statement%20of%20Cash%20Flows) This fiscal year, the Group's net cash outflow from operating activities was **HKD 10.555 million**, largely consistent with **HKD 8.279 million** in the prior year, while financing activities generated a net cash inflow of **HKD 11.19 million**, primarily from loans from former associates and major shareholders, resulting in a net increase in cash and cash equivalents of **HKD 0.635 million** and an ending balance of **HKD 3.703 million** | Item (HKD thousands) | FY2025 | FY2024 | | :--- | :--- | :--- | | **Net Cash Used in Operating Activities** | (10,555) | (8,279) | | **Net Cash From Financing Activities** | 11,190 | 10,321 | | **Net Increase in Cash and Cash Equivalents** | 635 | 2,042 | | **Cash and Cash Equivalents at End of Period** | 3,703 | 3,075 | [Notes to the Consolidated Financial Statements](index=71&type=section&id=Notes%20to%20the%20Consolidated%20Financial%20Statements) This section provides detailed notes to the financial statements, explaining accounting policies, key judgments, and estimates, with highlights including a detailed discussion on the going concern assumption (Note 3), segment information (Note 6), specifics and assumptions of intangible asset impairment tests (Note 16), and terms, changes, and accounting treatment of convertible bonds (Note 22), offering crucial context for understanding the company's financial position, operating results, and auditor's opinion - Note 3 elaborates on management's rationale for preparing financial statements on a going concern basis despite significant uncertainties, listing various mitigating measures including shareholder financial support, debt restructuring, and new financing plans[428](index=428&type=chunk)[429](index=429&type=chunk)[434](index=434&type=chunk) - Note 16 discloses changes in key assumptions for the impairment test of oral insulin R&D intangible assets, including commercialization delayed to **Q3 2028**, discount rate increased from **26.78%** to **31.53%**, and gross margin reduced from **56%** to **39%**, directly leading to an **HKD 297 million** impairment loss[696](index=696&type=chunk)[705](index=705&type=chunk)[709](index=709&type=chunk) - Note 22 details the terms, changes, and accounting treatment of multiple convertible bonds issued by the company, noting significant term modifications to Convertible Bond One related to a major shareholder and the new issuance of Convertible Bond Six during and after the reporting period[750](index=750&type=chunk)[761](index=761&type=chunk)[815](index=815&type=chunk) [Financial Summary](index=184&type=section&id=Financial%20Summary) [Five-Year Financial Summary](index=184&type=section&id=Financial%20Summary) This chapter presents key performance and financial position data for the Group's past five fiscal years, showing a continuous decline in revenue since FY2021, significant fluctuations in profitability with the largest loss recorded in FY2025, and a consistent reduction in net assets over the past five years, indicating a weakening overall financial strength | Fiscal Year Ended March 31 (HKD thousands) | 2025 | 2024 | 2023 | 2022 | 2021 | | :--- | :--- | :--- | :--- | :--- | :--- | | **Revenue** | 2,091 | 6,593 | 8,075 | 11,145 | 15,189 | | **(Loss) / Profit for the Year** | (570,346) | 98,707 | (254,671) | 36,431 | (212,155) | | **Net Assets** | 25,341 | 140,562 | 140,562 | 395,266 | 358,706 |

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） 自願性公告 委任為首席技術官 領航醫藥及生物科技有限公司（「本公司」）董事「( 董事」）會（「董事會」）欣然宣佈 李沛倫博士將由二零二五年七月二十九日起獲委任為本公司之首席技術官。 李沛倫博士，31歲，於清華大學姚班取得本科學位，並於清華大學交叉資訊研 究院獲得博士學位。畢業後就職於樹圖區塊鏈研究院至今，擔任技術專家。研 究方向是區塊鏈和分散式系統。 作為負責人承擔了2023年國家「區塊鏈」重點專項下設課題《超大規模區塊鏈底 層關鍵技術及系統研發》。在OSDI、ATC、SoCC等多個計算機系統國際會議發 表多篇論文，區塊鏈領域研究成果總引用量500餘次。申請發明專利十餘項， 其中三項美國發明專利已獲授權。 承董事會命 領航醫藥及生物科技有限公 ...